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Background: The contribution of hepcidin as a regulator of iron metabolism & erythropoiesis on the severity of
anemia in sickle cell disease (SCD) remains poorly characterized, especially in Sub-Saharan African populations.
The aims of the studywere to determine if hepcidin is associatedwith severity of steady-state anemia in SCD and
to investigate factors associated with hepcidin and anemia in SCD.
Methods: Archived samples from 199 Tanzanian children, 56% boys aged 3–18 with laboratory-conﬁrmed SCD
were analysed based on recorded averaged steady-state hemoglobin (ASSH) quartiles (lowest vs. highest).
Univariable and multivariable logistic regression was used to assess associations with ASSH quartiles.
Findings: In univariable analysis, hepcidin b5·5 ng/mLwas associated with increased odds of being in the lowest
ASSH quartile (OR 2·20; 95%CI 1·2–3·93) but which was limited to girls (OR 4·85, 95%CI 1·79–13·09, p= .046
for interaction). In multivariable analyses including either reticulocyte percentage or erythropoietin, lower
hepcidin remained signiﬁcantly associated with lowest ASSH quartile, although the hepcidin-sex interaction
no longer reached statistical signiﬁcance. No associations with ASSH quartile were observed for markers of in-
ﬂammation, hemolysis or potential iron markers except for microcytosis, associated with higher ASSH, but
which was confounded by reticulocyte percentage and alpha-thalassaemia status.
Interpretation: Hepcidin is lower in more severely anaemic children with SCD independent of inﬂammation or
markers of erythropoiesis.
Funding: Funding sources include TheWellcome Trust (080025, 095009, 094780& 070114),MRC-UK (MC-A760-
5QX00), NIHR Oxford Biomedical Research Centre, and the Bill and Melinda Gates Foundation (“Hepcidin and
Iron in Global Health”, OPP1055865).
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Sickle cell disease (SCD) is one of the most common inherited dis-
eases with the majority of the burden occurring in Sub-Saharan Africa
and India, settings where iron deﬁciency is also common. [1] SCD has
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Research in Context
Sickle cell disease (SCD) is one of the most common inherited
disorders globally, affects hemoglobin production, and is a
major cause of child mortality and poor health, most promi-
nently in Sub-Saharan Africa. Anemia is a defining feature of
SCD, but the relative causes of the degree of severity are in-
completely understood. Hepcidin downregulates iron absorp-
tion and supply to tissues in inflammation and infection and
levels decrease when iron is limited or red cell production is
increased or under low oxygen conditions. In this study, we
show that low hepcidin was associated with severe anemia in
children with SCD, independent of markers of inflammation
or erythropoietic drive and that this effect appeared to be lim-
ited to girls.
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a range of clinical manifestations, including anemia from increased he-
molysis. [2] SCD is also associated with an increased risk of mortality,
contributing signiﬁcantly to under-ﬁve mortality in Sub-Saharan
Africa. [3]
Low iron status has not been considered a signiﬁcant contributor to
the degree of severity of anemia in SCD as it is assumed that iron absorp-
tionwould increase tomeet the increased erythropoietic need. Further-
more, as children with SCD may receive repeated blood transfusions,
iron overload is more of a concern. [4] An increased understanding of
the regulation of iron metabolism, and in particular the role of hepcidin
a 25-amino-acid peptide hormone synthesized by hepatocytes as a key
negative-feedback regulator of iron status, suggests that sickle-related
processes of increased erythropoiesis and inﬂammation may have con-
ﬂicting effects on hepcidin and hence iron status. [5] Hepcidin blocks
iron absorption across the gut and iron efﬂux from the reticulo-
endothelial system. Hepcidin expression is increased by inﬂammation
and results in a hypoferremic state, which is an important anti-
infective response. [6] Hepcidin expression is decreased by erythropoi-
esis and hypoxia, thereby increasing iron absorption and release of body
iron to meet increased erythron demand. [6]
The contribution of iron deﬁciency to anemia in patients with SCD
living in areas where nutritional iron deﬁciency anemia is common is
unknown. Themeasurement of iron status is complicated by chronic in-
ﬂammation and increased erythropoiesis that confound biomarkers of
iron status. [7] The relative, quantitative effects of these processes com-
pared to iron status on iron markers are not known. Limited data re-
garding sensitivity and speciﬁcity of iron markers in SCD exist. Low
serum ferritin is speciﬁc for iron deﬁciency but in SCD has low sensitiv-
ity due to effects of inﬂammation. [8] Transferrin saturation is decreased
in iron deﬁciency but can also be decreased by the hypoferremic acute
phase response to infection and inﬂammation. The gold standard
method of iron staining in bone marrow biopsies is rarely conducted;
but in one small study in 60 Indian SCD adult patients, 28% were re-
ported to have absent stainable iron in bone marrow aspirates. Impor-
tantly, although the speciﬁcity of ferritin b30 ng/mL for iron deﬁciency
by bone marrow was 99%, the sensitivity was only 32%, indicating iron
deﬁciency may be present at higher ferritin concentrations in this con-
dition. [8]
The severity of anemia in SCD may also be affected by the co-
inheritance of other SCD modifying polymorphisms, including the α-
thalassaemia 3·7 deletion and glucose-6-phosphate dehydrogenase
(G6PD) deﬁciency [9]. Co-inheritance of α-thalassaemia in SCD mod-
iﬁes red cell indices and results in decreased hemolytic markers. [10]
In some reports, it has also been associated with effects on total hemo-
globin and steady-state hemoglobin level. [11] G6PD deﬁciency results
in decreased capacity to reduce oxidized glutathione via NADPH, and
thus the reduced ability of red cells to counteract oxidant stress. [10]
G6PD deﬁciency (A-genotype) in sickle cell anemia is associated with
lower hemoglobin but not increased hemolysis. [12]
Iron deﬁciency in non-SCD populations is associated with reduced
cognitive development and function and in SCDmay increase the sever-
ity of anemia, with consequent reduction in quality of life and survival.
[13,14] Paradoxically, there are reports that patients with SCD in iron-
deﬁcient states may have better SCD-related clinical outcomes. [15,16]
Levels of hemolysis and steady-state hemoglobin level have been used
to differentiate severity of disease in SCD. [17]
Here, we sought to determine if hepcidin is associated with lower or
higher average steady-state hemoglobin (ASSH) level in children with
SCD; and to evaluate how such an effect might be mediated.
2. Methods
2.1. Study Design and Population
The study was conducted in children enrolled in the Muhimbili
Sickle Cohort (MSC) in Dar-es-Salaam, Tanzaniawho regularly attended
the outpatient clinic between 2006 and 2009. [14] Samples were se-
lected for analysis from children in the lowest or highest average
(over 12 months) steady-state hemoglobin (ASSH) quartile within
their age group (HbQ1 or HbQ4). Selecting comparison populations
based on usual hemoglobin status, rather than hemoglobin on a single
day, reduced potential variability. Prospectively collected and archived
steady-state plasma and serum sampleswere selected as per the criteria
outlined below from children aged 3–18 years on the day of sample col-
lection. At that time, routine penicillin prophylaxis and pneumococcal
vaccination had not been implemented and no childrenwere on regular
blood transfusions. Venous blood for blood counts and peripheral oxy-
gen saturation (SpO2) using pulse oximetry (Nelcor Haywood, CA or
Masimo Radical, Irvine CA, USA) were routinely collected at these clinic
visits. The deﬁnition of steady-state for selection of blood samples to be
assessed for the laboratory investigations and for the calculation of
ASSH was deﬁned as a routine scheduled outpatient clinic visit in the
absence of recorded pain, fever (temperature N 37·4 °C), or current/
recent malaria infection (malaria rapid test or slide positive). Samples
were further excluded if hospitalization was known to have occurred
within a month of sample collection, or were probable HbSβ+. Other-
wise, all individualswereHbSS diagnosed by quantiﬁcation of hemoglo-
bin fractions performed by high performance liquid chromatography
(HPLC) using the β-thalassaemia Short Program on the Variant I
analyser (BioRad, Hercules, CA, USA).
2.1.1. Laboratory Procedures
Blood counts (Pentra 60, Horiba ABX, Kyoto, Japan) were routinely
collected on EDTA samples. Fetal hemoglobin was quantiﬁed using
HPLC. At annual visits, serum samples were collected for routine clinical
chemistry analyses (Roche Cobas Mira, New York or Abbott Architect,
New York, USA) as part of MSC follow-up and included liver function
tests; aspartate transaminase (AST), alkaline phosphatase (ALP) and di-
rect and indirect bilirubin, plus lactate dehydrogenase (LDH) as a
marker of hemolysis. Remaining plasma and serum samples were ar-
chived at−80 °C. Serum ferritin, serum iron, transferrin, C-reactive pro-
tein (CRP) and α-1 acid glycoprotein (AGP) were measured in archived
samples in batches on an automated analyser (Roche Cobas Mira, New
York). Plasma erythropoietin (EPO) and soluble transferrin receptor
(sTfR)weremeasured using ELISA (R&D systems) as permanufacturer's
instructions. Plasma hepcidin was measured with a competitive ELISA
(Hepcidin-25 [human] EIA Kit, Bachem)by a trained laboratory scientist
using an adapted method as published elsewhere. [18] Hepcidin:trans-
ferrin saturation and hepcidin: ferritin ratios were calculated as surro-
gate measures of hepcidin expression on circulating and stored iron
respectively, as previously described [19,20]. All samples were analysed
in the Muhimbili Sickle Cohort research laboratory in Muhimbili Na-
tional Hospital, Tanzania. Standards and samples were analysed in du-
plicate or triplicate (hepcidin). Samples with readings outside the
standard curvilinear region were repeated at appropriate dilutions.
Sample results with a coefﬁcient of variation over 10% (≥12% for
hepcidin) were repeated.
Co-inheritance of potential SCD modifying genotypes including α–
thalassaemia genotype for the 3·7 deletion and The 202- and 376-
single nucleotide polymorphisms (SNPs) (rs1050828 [G-202A] &
rs1050829 [A-376G]), the combined inheritance resulting in the A- phe-
notype of glucose 6-phosphate dehydrogenase (G6PD) deﬁciency were
assessed as previously reported. [9]
2.1.2. Statistical Analysis
Data were analysed using Stata IC (StataCorp LP v14·1). Adjustment
for within individual clustering for repeated samples was accounted for
using robust standard errors. Statistical signiﬁcance was set as p ≤ 0·05.
Missing data of ≥5% per variable with a pattern of missingness that was
random or completely random was imputed using chained equations
and n= 20 imputation sets. [21]
159N. Lee et al. / EBioMedicine 34 (2018) 158–164
Univariable analysis accounting for repeated observations in some
individuals was performed using logistic regression. Results were re-
ported as odds ratios with associated 95% conﬁdence intervals. Contin-
uous variables were checked to ensure that they fulﬁlled linearity
assumptions on regression. If this was not the case, then a strategy of
transformation using fractional polynomials was employed in order to
avoid categorizing variables. [22] Results were scaled as necessary to
present interpretable data. Dataset was also tested for possible effect
modiﬁcations.
Multivariable analysis was performed, with a variable selection
strategy stratiﬁed to include at least one variable from each of the
major biological processes known to inﬂuence SCDprocesses. This strat-
iﬁcation included variables describing a general inﬂammatory state,
iron metabolism, and reticulocyte percentage or serum erythropoietin
as a marker of erythropoietic drive. Logistic regression was performed
as the primary multivariable modelling tool, adjusted for age and sex.
2.1.3. Ethics Statement
The study received ethical approval from Muhimbili University of
Health and Allied Sciences reference MU/RP/AEC/VOL XI/33) and the
London School of Hygiene & Tropical Medicine (reference 5158). In-
formed consent was obtained from patients or guardians at screening
and at enrolment into the cohort.
2.1.4. Role of the Funding Sources
The stated funding sources did not have any role in the in study de-
sign; in the collection, analysis, and interpretation of data; in thewriting
of the report; or in the decision to submit the paper for publication.
3. Results
A total of 269 samples were analysed from 199 children (Fig. 1).
Fifty-nine children had a second sample, and 11 children had a third
sample included in the analysis. The range of hemoglobin for ASSH
levels in the two quartile groups was 5·2–6·7 g/dL in the HbQ1 group
and 8·1–10·6 g/dL in the HbQ4 group (Fig. 1). Hemoglobin assessed
at the same timepoint as the biochemical measurements was outside
the ASSH range for 8% of those in HbQ4 and 9% of those in HbQ1 group.
Univariable analysis of the two ASSH quartile groups by age, sex,
markers of potential iron status, red cell indices, markers of inﬂamma-
tion and hemolysis, erythropoietin, hepcidin, SpO2, α-thalassemia ge-
notype, G6PD status, and fetal hemoglobin level are shown in Table 1.
Boys were signiﬁcantly more likely to be in the more severely anaemic
HbQ1 group (OR 2·40; 95%CI 1·28–4·50), but age was not associated.
Inﬂammatory markers did not differ between ASSH quartile groups.
None of themeasured potential ironmarkers were associated with par-
ticular ASSH quartiles. The proportions of children classiﬁed as iron de-
ﬁcient by serum ferritin b30 g/L, were 11% and 7% in the most severely
anaemic HbQ1 and least severely anaemic HbQ4 groups respectively (p
= 0·301), compared to 16% and 15% with transferrin saturation b 16%
in the HbQ1 and HbQ4 groups respectively (p = 0·574). Microcytosis
was more common in the less anaemic HbQ4, 60% compared to 39% in
HbQ1 (p=0·002). The HbQ1 groupwas at higher odds of increased re-
ticulocyte percentages compared to the HbQ4 group (OR 1·05, p =
0·036). The proportion of children with hepcidin levels below
5·5 ng/mL, previously shown to indicate iron deﬁciency and increased
iron utilisation in Gambian children, was signiﬁcantly higher at 73% in
the most anaemic HbQ1 group compared to 55% in HbQ4 group (P =
0·007). [18] Both the hepcidin/ferritin and hepcidin/transferrin satura-
tion ratios were lower in the HbQ1 group (OR 0.72, p= 0.003 and OR
0.71, p = 0.003 respectively).
Increased serum EPO was associated with increased odds for HbQ1
(OR 1·009; 95%CI 1·00–1·02). None of the measures of hemolysis
were associatedwithHbQ group. A higher SpO2was associatedwith de-
creased odds of being in the HbQ1 group (OR 0·72; 95%CI 0·63–0·83).
Hepcidinb5·5 ng/mLwas associatedwith increased odds of being in the
HbQ1 group (OR 2·20; 95%CI 1·23–3·93). Co-inheritance of an increas-
ing number ofα-thalassaemia mutations showed a trend for decreased
odds of being in the Hb1Q groupwith two deletions having a signiﬁcant
protective effect (−α/−αdeletion - OR 0·21; 95%CI 0·07–0·58), whilst
increased fetal hemoglobin levels were similarly associated with de-
creased odds (OR 0·74; 95%CI 0·66–0·84). The number of α-
Fig. 1. Flow chart of study population and sample analysis.
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thalassaemia deletions was also associated with microcytosis (43% one
deletion, 36% two deletions).
The results of multivariable analyses of quartile groups are shown
in Table 2. Adjusted for age, sex, ferritin, inﬂammation and reticulo-
cyte percentage or erythropoietin levels, low hepcidin levels were
independently associated with increased odds of being in the more
severely anaemic HbQ1 group. In addition, we tested for a potential
interaction between low hepcidin and sex and observed a signiﬁcant
interaction in which the odds of low hepcidin being associated with
severe anemia was limited to females (OR 4·85, 95%CI 1·79–13·09
in girls vs 1·44, 95%CI 0·71–2·92 in boys) with a Mantel Haenzel
test for heterogeneity of p = 0·046. Although this effect remained
present in the multivariable model, the interaction termwas not sta-
tistically signiﬁcant.
We investigated how hepcidin is associated with markers of known
pathways affecting its expression, and whether these differed by quar-
tile group by assessing associations between hepcidin with inﬂamma-
tory markers (Fig. 2 A & B), erythropoeitin (Fig. 2C), and SpO2
(Fig. 2D). and between hepcidin and ferritin levels, in the absence and
presence of inﬂammation (Fig. 2E & F).
There were no associations between age and sex on hepcidin con-
centrations. Hepcidin was positively associated with serum ferritin (r2
= 0·4, P b 0·001), which did not differ by quartile group, with similar
slopes of the two regression lines. When the association between
hepcidin and ferritin for each quartile group was examined in the pres-
ence or absence of inﬂammation, there were no apparent differences
(Fig. 2 E&F). Hepcidin levels also signiﬁcantly increased with increasing
inﬂammation (CRP; r2= 0·12, p b 0·001), and did not differ by quartile
Table 1
Factors associated with steady-state, averaged hemoglobin ﬁrst and last quartile (HbQ1 & HbQ4). Univariable analysis using logistic regression for association with HbQ1, adjusting for
multiple sample observations.
Total sample observations Low steady state Hgb (HbQ1) High steady state Hgb (HbQ4) OR [95% CI] P-value
Sex (total group n= 269)
Male 150 89 (66·4%) 61 (45·2%) 2·40 [1·28–4·50] 0·006
Age category (on day of sample) 269
1–3 years 3 (2·4%) – 0·94 [0·60–1·47] 0·792
4–6 years 15 (11·2%) 22 (16·3%)
7–12 years 93 (69·4%) 86 (63·7%)
13–17 years 23 (17·2%) 27 (20·0%)
Inﬂammatory markers
WBC (x 109/L) 264 14·4 (11·85–17·15) 12·5 (9·82–16·30) 4·80 (2·0.00–11·53) b0.001
AGP (mg/dL) 266 125·93 [97·41–158·08] 117·86 [88·85–144·72] 1·30 [0·62–2·71] 0·482¶
AGP elevated [N120 mg/dL] 68 (51·5%) 64 (47·8%) 1·16 [0·70–1·94] 0·566
CRP [mg/L] 266 4·19 [2·29–8·40] 3·98 [1·85–6·98] 1·12 [0·89–1·43] 0·324¶
CRP elevated [≥ 3 mg/L] 82 (62·1%) 84 (62·7%) 0·98 [0·57–1·68] 0·930
Potential iron markers
Ferritin (μg/L) 266 116·65 [57·75–229·35] 163·15 [87·70–254·70] 0·79 [0·59–1·05] 0·102¶
Transferrin (g/L) 266 3·03 [2·52–3·65] 2·88 [2·53–3·54] 1·13 [0·84–1·51] 0·435
Transferrin saturation [%] 263 26·98 [18·61–40·31] 26·42 [18·98–36·14] 1·01 [0·99–1·03] 0·315
sTfR (mg/L) 259 15·01 [10·88–62·64] 13·24 [9·01–51·38] 1·00 [0·997–1·013] 0·257
sTfR-F index 256 3·42 [2·17–11·60] 2·98 [1·73–10·06] 1·02 [0·98–1·06] 0·283
Hypoferritinaemia (ferritin b30 μg/L) 15 (11%) 10 (7%) 1·59 [0·66–3·83] 0·301
sTfR-F indexN5·6 [32] 51 (40·8%) 58 (44·3%) 0·87 [0·53–1·42] 0·574
Transferrin saturation b 16% 21 (16%) 20 (15%) 1·07 [0·53–2·17] 0·853
Red cell indices
MCV (fL/cell) 264 84·00 [78·50–87·45] 79·00 [71·50–85·00] 1·03 [0·97–1·08] 0·323
MCHC (g/dL) 260 32·30 [31·40–33·20] 32·30 [31·50–33·20] 0·970 [0·856–1·10] 0·637
Microcytic MCVa 50 (38%) 79 (60%) 0·41 [0·23–0·72] 0·002
MCHC b32 g/dL 48 (37%) 51 (39%) 0·99 [0·73–1·32] 0·962
Erythropoietic drive
EPO [μIU/mL] 241 110·42 [76·95–207·41] 54·96 [36·88–81·47] 1·009 [1·001–1·016] 0·016
Reticulocyte [%] 151 12.9 [9·3–16·2] 10.2 [6·2–15·8] 1·05 [1·00–1·10] 0·036
Hemolytic markers
LDH [IU/L] 190 688·50 [534·50–997·50] 520·50 [377·00–908·00] 0·43 [−0·28–1·14] 0·234
Indirect bilirubin [μmol/L] 248 49·62 [24·00–83·10] 30·16 [15·83–56·60] 1·005 [0·999–1·012] 0·123
Hemoglobin oxygen saturation
SpO2 (%) 217 96 [94·5–98·0] 98 [97·0–100·0] 0·72 [0·63–0·83] b0·001
Hepcidin
Hepcidin ng/mL 255 2·00 [0·64–6·16] 4·36 [1·50–9·72] 0·74 [0·60–0·90] 0·003
Hepcidin b5·5 ng/mL 95 (73·1%) 69 (55·2%) 2·20 [1·23–3·93] 0·007
Hepcidin/Ferritin ratio 253 0.02 (0.01–0.03) 0.03 (0.01–0.06) 0.71 (0.57–0.89) 0.003
Hepcidin/Tranferrin saturation ratio 250 0.07 (0.03–0.17) 0.15 (0.07–0.46) 0.72 (0.58–0.89) 0.003
α-thalassaemia 3·7 Deletion 238
Wild Type (αα/ αα) 93 59 (49%) 34 (29%)
1 Deletion (−α/ αα) 96 48 (40%) 48 (41%) 0·58 [0·27–1·23] 0·155
2 Deletions (−α/− α) 49 13 (11%) 36 (31%) 0·21 [0·07–0·58] 0·003
G6PD deﬁciency 216
No deﬁciency 171 85 (77%) 86 (81%)
Female heterozygous 14 8 (7%) 6 (6%) 1.35 [0·39–4·62] 0·634
Male and female homozygous 31 17 (15%) 14 (13%) 1.22 [0·43–3·53] 0·702
Fetal hemoglobin (%) 228 4 [1·7–5·2] 6·7 [4·1–9·7] 0·74 [0·66–0·84] b0·001
Continuous variables are presented as medians with interquartile range in brackets. Binary or categorical variables are presented as the numerator and percentages in brackets. Variables
chosen to transformusing fractional polynomials fulﬁlled criteria of non-linearity. Normal ranges are as per international standards except for the followingwhich are either for factors not
universally harmonized or are speciﬁc to the Tanzanian child population: WBC 109/L (1–5 years 3·7–13·2, 5–13 years 3·7–9·1, 13–18 years (3·2–10·3); erythropoietin 3·1–16·5 IU/L.
[33, 34] indicates variable fulﬁlling criteria for imputation, descriptive statistics reported for original dataset ¶ indicates ﬁrst-degree fractional polynomial power of 0. a Cut-offs for MCV
(fL) were MCV b 75 if age 1–3 years, MCV b 79 if age 3–5 years, MCV b 80 if age 6–11 years, MCV b 82 if age 11-14 years, MCV 15–74 if age 15–74 years [7].
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group. Hepcidin was not associated with EPO levels (r2 =−0·01, p=
0·15), with no evidence of difference between the quartile groups. Fi-
nally, there was no evidence of an association between hepcidin and
SpO2 (r2 = 0·0002, p = 0·826) (Fig. 2D).
4. Discussion
It is important to determine the aetiology of severe anemia in SCD
patients at steady-state to improve management and develop targeted
interventions. We observed that low hepcidin levels were associated
withmore severe anemia, occurring in the absence of differences in pos-
sible iron markers between the groups. Thus, despite the limitations of
iron markers in SCD, we can tentatively conclude that high hepcidin
levels, and an inability to absorb and incorporate iron, are not likely to
be a proximal cause of more severe anemia in this population. As ex-
pected, increased reticulocyte percentage was associated with more se-
vere anemia but inﬂammation was not associated.
Hepcidin in African children without SCD has been suggested as a
potential marker to indicate both low iron status, and the ability to re-
ceive and utilize iron supplements in anaemic African children. [18,23]
Using the same cut off as in this study, more children in HbQ1 group
had low hepcidin. Considering the proportion of children with inﬂam-
mation, the proportion of children with hepcidin below this cut off
was high in both groups (73% vs 55%). We do not know how hepcidin
may relate to iron status in our SCD population. High levels of erythro-
poiesis or hypoxia may be expected to override the effect of inﬂamma-
tion to keep hepcidin low, but this is not supported by our observation
of limited associations between hepcidin and EPO, CRP or SpO2. EPO
might not be the best marker of erythropoietic drive as it does not
take into account EPO sensitivity and therefore reticulocyte percentage
may be a better indicator of erythropoietic response. However, the asso-
ciation between lowhepcidin and anemia statuswas largely unchanged
when adjusting for either of these markers. It remains unclear why the
association between low hepcidin andmore severe anemia was limited
to girls. The majority of the study population were pre-pubertal, as pu-
berty andmenarche are signiﬁcantly delayed in SCD, thusmaking it less
likely that there was more true iron deﬁciency in girls due to menstru-
ation. It would be instructive to measure the EPO-stimulated,
erythroblast-derived hormone erythroferrone, which supresses
hepcidin. Erythroferrone is increased in humans after EPO administra-
tion, and in thalassaemic patients, but levels in SCD are as yet unknown;
we would hypothesise it may be elevated in the most anaemic patients
if they are undergoing increased erythropoiesis. [24] There was a strong
correlation betweenhepcidin and ferritin (r2=0·4, p b 0·001) and only
a weak association with inﬂammatory markers. If hepcidin levels are
low, and probably in the order of the current cut off, children should
be able to absorb and utilize available iron in the diet if it were required.
The prevalence of lowserum ferritin (b30 μg/L) in our total studypop-
ulation was 9·4%. It is possible that more children have low body iron
stores than this ﬁgure suggests, as low serum ferritin is highly speciﬁc
but insensitive for iron deﬁciency in SCDwhen assessed by bonemarrow
aspirate staining. [8] When limited to children without low-grade or se-
vere inﬂammation this increased to 17·5%, similar, to the prevalence as-
sociated by transferrin saturation. In Yemeni children with SCD the
prevalence of low serum ferritin was 25% when using the criteria of
serum ferritin b30 μg/L if CRP b 10 mg/L, or b 70 μg/L if CRP N 10 mg/L.
[25] If we used these same criteria, the prevalence of low serum ferritin
in our population would be 10·5%, suggesting that these cut-offs do not
adequately deal with the effect of inﬂammation on ferritin. The observed
increased MCV and decreased proportion of microcytosis in the HbQ1
group may result from an increased rate of erythropoiesis in this group,
as indicated by greatly increased EPO, and from less frequent co-
inheritance of α-thalassaemia deletions which are associated with
microcytosis. From the observations of the potential iron markers we
can conclude that either: (i) iron deﬁciency although present in some
children is not contributing to degree of anemia, or; (ii) these iron
markers are not adequately capturing iron status in our SCD population.
We propose that the 2nd option is the more likely. Dietary assessment
of iron intakes might be helpful to assess if low-bioavailable iron diets
are contributing to anemia severity in this population.
Few previous studies have attempted to characterize iron marker or
other parameters and hepcidin in patients with sickle cell disease. Sim-
ilar to our results, in a SCD cohort of adults in Holland, it was reported 5/
16 (HbSS/SC & HbSβ0) had serum hepcidin levels below the normal
range (measured by mass spectrometry, b1 mmol/L), and these tended
to be in patients with lower ferritins and more severe anemia. [20] In
American adults, serum hepcidin in heavily transfused SCD patients
had a similar degree of correlation with serum ferritin but a larger neg-
ative correlation with EPO (r2 =−0·34, p-0·03), which in our dataset,
did not reach statistical signiﬁcance – possibly due to the extremes of
hemoglobin concentration resulting from our study design. [26] Our ap-
proach of selecting samples from children at the extreme ranges of av-
eraged steady-state hemoglobin has limitations compared to
analysing samples from across the range of hemoglobin, but this design
was selected as the most parsimonious in the context of the very little
available information in SCD at the time.
Low averaged steady state hemoglobin levels were associated with
high EPO, increased reticulocyte %, lower SpO2, the absence of co-
inheritance ofα-thalassaemia deletions, and lower levels of fetal hemo-
globin. No association was seen for G6PD mutations. In Jamaican SCD
patients Serjeant et al. reported α-thalassemia status, sex and fetal he-
moglobin to be associatedwith hemoglobin levels. [11] The relationship
between erythropoietin and anemia in SCD has been previously docu-
mented in an American SCD cohort. [27]
Table 2
Multivariablemodel for associations with low steady-state averaged hemoglobin quartile [HbQ1], adjusted for age and sex a-priori. Sample size of observations after imputations is n=248.
Variable Adjusted OR [95%
CI] p-value
Adjusted OR° [95%
CI] p-value
Adjusted OR (inclusive of hepcidin-sex
interaction⁎) [95% CI] p-value
Adjusted OR° (inclusive of hepcidin-sex
interaction⁎⁎) [95% CI] p-value
Decreased Hepcidin 2·38 [1·24–4·56] 0·009 2·27 [1·14–4·54] 0·020
• b5.5 ng/mL in females – – 4·42 [1·69–11·60] 0·003 4·83 [1·40–16·60] 0·013
• b5.5 ng/mL in males – – 1·54 [0·62–3·87] 0·355 1·47 [0·60–3·62] 0·405
Ferritin (μg/L)a 1·001 [0·999–1·002] 0·493 1·000 [0·998–1·003] 0·776 1·000 [0·999–1·002] 0·612 1·000 [0·998–1·003] 0·886
Presence of inﬂammationa 1·11 [0·60–2·03] 0·747 0·96 [0·52–1·77] 0·893 1·06 [0·57–1·96] 0·851 0·92 [0·49–1·73] 0·805
Reticulocyte (%)b 1·06 [1·01–1·11] 0·028 – 1·06 [1·00–1·11] 0·033 –
Erythropoietin (μIU/mL) – 1·01 [1·00–1·01] 0·009 – 1·008 [1·002–1·015] 0·007
Age 0.96 (0·86–1·06) 0·405 1.00 (0·90–1·12) 0·984 0·96 [0·86–1.07] 0.436 1·00 [0·90–1.12] 0.942
Male Sex 2.53 (0·06–0·93) 0·039 2.99 (1·51–5·95) 0·002 – –
Male sex in hepcidin N5.5
(baseline group)
– – 5·19 (1·68–16·03) 0.004 6·96 (1·77–27·35) 0.005
° Independent factor inserted into model as surrogate of erythropoiesis is erythropoietin levels.
a Presence of inﬂammation deﬁned as serum CRP N 5 mg/L or serum AGP N 120 mg/L.
b Imputed continuous range of reticulocytel.
⁎ p-Value for interaction term in multivariable model is p = 0.115.
⁎⁎ p-Value for interaction term in multivariable model is p = 0.120.
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Fig. 2.A–E - Association of serumhepcidin by ASSH quartile groupwith inﬂammatorymarkers: (2A and B) serumAGP and CRP; (2C) erythropoietin; (2D)Oxygen Saturation; and (2E and
F) ferritinwith andwithout inﬂammation. Red= low steady-state hemoglobin quartile (HbQ1); Blue=high steady-state hemoglobin quartile (HbQ4). Hepcidin cut-off demonstrated as
5.5 ng/mL. Dotted lines on the Y-axis refer to a hepcidin cut-off point at 5.5 ng/mL. Dotted lines on the X-axis are speciﬁed in the legend below. (2A) AGP cut-off demonstrated as 120mg/dL
HbQ1 correlation coefﬁcient 0·748 [95%CI 0·051–1·444], R 0·185, p= 0·036; HbQ4 correlation coefﬁcient 1·064 [95%CI 0·313–1·814], R 0·246, p= 0·006) (2B) CRP cut-off demonstrated as 5
mg/L.HbQ1 correlation coefﬁcient 0·585 [95%CI 0·345–0·825], R 0·393, p b 0·001; HbQ4 correlation coefﬁcient 0·449 [95%CI 0·239–0·658], R 0·359, p b 0·001) (2C) Erythropoetin cut-off
demonstrated at 9 μIU/mL. HbQ1 correlation coefﬁcient− 0·133 [95%CI -0·527–0·261], R -0·063, p = 0·505); HbQ4 correlation coefﬁcient− 0·291 [95%CI -0·682–0·100], R -0·136, p =
0·143 (2D) Oxygen saturation cut-off demonstrated as 97%. HbQ1 correlation coefﬁcient− 0·064 [95%CI -0·157–0·028], r2 0·018, p = 0·170); HbQ4 correlation coefﬁcient 0·012 [95%
CI -0·155–0·178], R -0·135, p = 0·889 (2E) Ferritin cut-off demonstrated as 30 g/L. HbQ1 correlation coefﬁcient 0·947 [95%CI 0·748–1·147], R 0·641, p b 0·001); HbQ4 correlation
coefﬁcient 1·024 [95%CI 0·784–1·263], R 0·608, p b 0·001 (2F) Red = HbQ1 with systemic inﬂammation; Orange = HbQ1 without systemic inﬂammation; Blue = HbQ4 with systemic
inﬂammation; Black = HbQ4 without systemic inﬂammation. Systemic inﬂammation deﬁned as AGP N 120 mg/dL and/or CRP N 5 mg/L. Without systemic inﬂammation - HbQ1 correlation
coefﬁcient 1·007 [95%CI 0·711–1·303], R 0·695, p b 0·001); HbQ4 correlation coefﬁcient 1·160 [95%CI 0·868–1·453], R 0·741, b0·001 With systemic inﬂammation - HbQ1 correlation
coefﬁcient 0·914 [95%CI 0·629–1·200], R 0·593, p b 0·001); HbQ4 correlation coefﬁcient 0·812 [95%CI 0·381–1·243], R 0·415, p b 0·001.
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Previous uncontrolled trials of iron supplementation in SCD have
shown moderate responses in hemoglobin to iron supplementation in
children with possible iron deﬁciency, deﬁned as either low transferrin
saturation, lowMCV for age or low ferritin. [28,29] Limited case reports
have suggested that relative iron deﬁciency in adults may be clinically
beneﬁcial by decreasing rates of sickling episodes due to lower per cell
hemoglobin concentration. [16] α–thalassaemia is also hypothesized
to be protective in this manner, by reducing concentration dependent
polymerization of HbS. [30] Thus, lower iron status could counter-
intuitively result in higher total hemoglobin in SCD. Therefore, it
would be essential to carefully monitor the effects of giving iron to as-
sess the relative advantages and risks. Targeting young children, who
are most at risk of iron deﬁciency from diets low in bioavailable iron
and low iron stores, at birth would seem sensible. Additionally, these
children should also be receiving penicillin prophylaxis and effective
anti-malarials (in malaria endemic areas) to reduce a potential effect
of an increased risk of infection and its effects with and without hy-
droxyurea assessed. [3,31]
In conclusion, we have shown that in children with SCD, lower
hepcidin levels are associated with lower steady- state hemoglobin, in-
dependent of EPO or reticulocyte % and markers of inﬂammation. Fac-
tors signiﬁcantly associated with hepcidin levels were serum ferritin
and CRP, although neither of these were independently associated
with anemia. Future studies are required to further characterize the re-
lationship between hepcidin, erythropoiesis and anemia, and to directly
assess the effect of iron supplementation in SCD on hepcidin levels and
iron absorption with a view to establish its role in the management of
SCD and possible iron deﬁciency.
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